- Home
- CYCC vs ALLR Comparison
CYCC vs ALLR Comparison
Compare CYCC & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- ALLR
- Stock Information
- Founded
- CYCC 1992
- ALLR 2004
- Country
- CYCC Malaysia
- ALLR United States
- Employees
- CYCC N/A
- ALLR N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- ALLR Health Care
- Exchange
- CYCC Nasdaq
- ALLR Nasdaq
- Market Cap
- CYCC 17.5M
- ALLR 15.8M
- IPO Year
- CYCC N/A
- ALLR N/A
- Fundamental
- Price
- CYCC $6.37
- ALLR $1.66
- Analyst Decision
- CYCC
- ALLR Strong Buy
- Analyst Count
- CYCC 0
- ALLR 1
- Target Price
- CYCC N/A
- ALLR $9.00
- AVG Volume (30 Days)
- CYCC 82.6K
- ALLR 21.5M
- Earning Date
- CYCC 11-11-2025
- ALLR 11-13-2025
- Dividend Yield
- CYCC N/A
- ALLR N/A
- EPS Growth
- CYCC N/A
- ALLR N/A
- EPS
- CYCC N/A
- ALLR N/A
- Revenue
- CYCC $10,000.00
- ALLR N/A
- Revenue This Year
- CYCC $137.21
- ALLR N/A
- Revenue Next Year
- CYCC N/A
- ALLR N/A
- P/E Ratio
- CYCC N/A
- ALLR N/A
- Revenue Growth
- CYCC N/A
- ALLR N/A
- 52 Week Low
- CYCC $3.08
- ALLR $0.61
- 52 Week High
- CYCC $597.60
- ALLR $3.91
- Technical
- Relative Strength Index (RSI)
- CYCC 37.28
- ALLR 59.12
- Support Level
- CYCC $5.92
- ALLR $1.78
- Resistance Level
- CYCC $8.82
- ALLR $1.92
- Average True Range (ATR)
- CYCC 0.58
- ALLR 0.25
- MACD
- CYCC -0.04
- ALLR 0.02
- Stochastic Oscillator
- CYCC 15.52
- ALLR 52.25
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.